Kymera Therapeutics (KYMR) News Today → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free KYMR Stock Alerts $32.87 -1.00 (-2.95%) (As of 06/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5 at 4:54 AM | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by UBS Group AGUBS Group AG grew its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 84.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 300,463 shares of the company's stock after acquiring aJune 4 at 3:50 AM | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Given "Buy" Rating at HC WainwrightJune 3, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Kymera Therapeutics (NASDAQ:KYMR)HC Wainwright reaffirmed a "buy" rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research note on Monday.June 1, 2024 | globenewswire.comKymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingMay 29, 2024 | globenewswire.comKymera Therapeutics to Participate in Upcoming June Investor ConferencesMay 24, 2024 | markets.businessinsider.comDemystifying Kymera Therapeutics: Insights From 5 Analyst ReviewsMay 24, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research report on Friday.May 23, 2024 | finance.yahoo.comKymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingMay 23, 2024 | globenewswire.comKymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingMay 23, 2024 | marketbeat.comTrexquant Investment LP Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Trexquant Investment LP acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 203,564 shares of the compaMay 22, 2024 | globenewswire.comKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual MeetingMay 20, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading 4.8% Higher Kymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.8%May 14, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 5.5% Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 5.5%May 14, 2024 | globenewswire.comKymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Inhibrx (INBX)May 8, 2024 | globenewswire.comKymera Therapeutics to Participate in Upcoming May Investor ConferencesMay 5, 2024 | finance.yahoo.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkMay 3, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSKymera Therapeutics (NASDAQ:KYMR - Get Free Report) announced its earnings results on Thursday. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The firm had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. During the same period in the previous year, the business earned ($0.70) EPS. The business's quarterly revenue was up 8.4% compared to the same quarter last year.May 3, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kymera Therapeutics Backed by Promising KT-253 Program Data and Upcoming ASCO Meeting AnticipationMay 3, 2024 | finance.yahoo.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comOppenheimer Trims Kymera Therapeutics (NASDAQ:KYMR) Target Price to $52.00Oppenheimer lowered their price objective on shares of Kymera Therapeutics from $53.00 to $52.00 and set an "outperform" rating on the stock in a research report on Friday.May 3, 2024 | finance.yahoo.comKymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 2, 2024 | investorplace.comKYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | msn.comKymera Therapeutics GAAP EPS of -$0.69 beats by $0.04, revenue of $10.3M misses by $2.75MMay 2, 2024 | globenewswire.comKymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business UpdateMay 1, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Trading Up 6.8%Kymera Therapeutics (NASDAQ:KYMR) Trading Up 6.8%May 1, 2024 | markets.businessinsider.comKymera Therapeutics earnings preview: what Wall Street is expectingMay 1, 2024 | msn.comKymera Therapeutics Q1 2024 Earnings PreviewApril 26, 2024 | marketbeat.comKymera Therapeutics (KYMR) Scheduled to Post Quarterly Earnings on ThursdayKymera Therapeutics (NASDAQ:KYMR) will be releasing earnings before the market opens on Thursday, May 2, Zacks reports.April 25, 2024 | globenewswire.comKymera Therapeutics to Report First Quarter 2024 Financial Results on May 2April 24, 2024 | investing.comKymera Therapeutics stock gets Outperform rating on positive outlookApril 24, 2024 | nasdaq.comCommit To Buy Kymera Therapeutics At $17.50, Earn 9% Annualized Using OptionsApril 23, 2024 | msn.comOppenheimer Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform RecommendationApril 22, 2024 | benzinga.comKymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)April 22, 2024 | marketbeat.comOppenheimer Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)Oppenheimer initiated coverage on shares of Kymera Therapeutics in a research note on Monday. They issued an "outperform" rating and a $53.00 target price for the company.April 18, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Up 4.5%Kymera Therapeutics (NASDAQ:KYMR) Trading 4.5% HigherApril 15, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Growth in Short InterestKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 9,060,000 shares, an increase of 8.8% from the March 15th total of 8,330,000 shares. Based on an average daily trading volume, of 752,000 shares, the days-to-cover ratio is presently 12.0 days.April 11, 2024 | marketbeat.comResearch Analysts Offer Predictions for Kymera Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYMR)Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Brookline Capital Management boosted their Q1 2024 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a research note issued on Monday, April 8th. Brookline Capital Management analyst L. Cann now aApril 9, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Holdings Lifted by Vanguard Group Inc.Vanguard Group Inc. increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,925,213 shares of the company's stoApril 8, 2024 | finanznachrichten.deKymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingApril 8, 2024 | globenewswire.comKymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingMarch 29, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and six have assignMarch 28, 2024 | investing.comKymera Therapeutics Inc (KYMR)March 20, 2024 | finance.yahoo.comKYMR May 2024 30.000 callMarch 19, 2024 | finance.yahoo.comKYMR Aug 2024 20.000 putMarch 18, 2024 | bizjournals.comBiotech upgrades to new Watertown digs with triple the spaceMarch 16, 2024 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth Sells 71,764 SharesMarch 14, 2024 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Major Shareholder Venture Fund X. L.P. Atlas Sells 42,302 SharesMarch 13, 2024 | marketbeat.comGSA Capital Partners LLP Has $710,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)GSA Capital Partners LLP raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 141.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,088 shar Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Final Masterpiece: “X-9840” (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. KYMR Media Mentions By Week KYMR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.440.73▲Average Medical News Sentiment KYMR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼53▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NRIX News Today EDIT News Today REPL News Today ALVR News Today ATRA News Today PCVX News Today EXEL News Today RVMD News Today HALO News Today CRSP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredExposed: 10 CENT Crypto to Explode May 20th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored